Cited 9 times in
Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 홍범기 | - |
dc.contributor.author | 김재훈 | - |
dc.date.accessioned | 2021-09-29T02:33:15Z | - |
dc.date.available | 2021-09-29T02:33:15Z | - |
dc.date.issued | 2020-10 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184984 | - |
dc.description.abstract | Purpose: Although the role of high-intensity lipid-lowering therapy in cardiovascular protection has broadened, concerns still exist about new-onset diabetes mellitus (NODM), especially in vulnerable patients. This study aimed to compare the effect of high-dose (4 mg/d) and usual dose (2 mg/d) pitavastatin on glucose metabolism in patients with hyperlipidemia and impaired fasting glucose (IFG). Methods: In this 12-month study, glucose tolerance and lipid-lowering efficacy of high-dose pitavastatin (4 mg [study group]) was compared with that of usual dose pitavastatin (2 mg [control group]) in patients with hyperlipidemia and IFG. The primary end point was the change of glycosylated hemoglobin (HbA1c) after 24 weeks of treatment. The secondary end points were as follows: (1) NODM within 1 year after treatment, (2) change of lipid parameters, (3) changes of adiponectin, and (4) change of blood glucose and insulin levels. Findings: Of the total 417 patients screened, 313 patients with hypercholesterolemia and IFG were randomly assigned into groups. The mean (SD) change in HbA1c was 0.06% (0.20%) in the study group and 0.03% (0.22%) in the control group (P = 0.27). Within 1 year, 27 patients (12.3%) developed NODM, including 12 (10.6%) of 113 patients in the study group and 15 (14.2%) of 106 in the control group (P = 0.43). The study group had a significantly higher reduction of total cholesterol and LDL-C levels and a higher increase in apolipoprotein A1/apolipoprotein B ratio (0.68 [0.40] vs 0.51 [0.35], P < 0.01). Implications: The high-dose pitavastatin therapy did not aggravate glucose metabolism compared with the usual dose therapy. Moreover, it had a better effect on cholesterol-lowering and apolipoprotein distribution in the patients with hyperlipidemia and IFG. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Excerpta Medica | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Apolipoprotein A-I / blood | - |
dc.subject.MESH | Apolipoproteins B / blood | - |
dc.subject.MESH | Blood Glucose / drug effects | - |
dc.subject.MESH | Cholesterol / blood | - |
dc.subject.MESH | Fasting | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Glycated Hemoglobin A / metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* | - |
dc.subject.MESH | Hypercholesterolemia / drug therapy* | - |
dc.subject.MESH | Hyperlipidemias / drug therapy* | - |
dc.subject.MESH | Lipids / blood | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Quinolines / administration & dosage* | - |
dc.title | Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia: A Randomized, Open-labeled, Multicentered, Phase IV Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hae-Young Lee | - |
dc.contributor.googleauthor | Ki-Hoon Han | - |
dc.contributor.googleauthor | Woo-Baek Chung | - |
dc.contributor.googleauthor | Sung-Ho Her | - |
dc.contributor.googleauthor | Tae-Ho Park | - |
dc.contributor.googleauthor | Seung-Woon Rha | - |
dc.contributor.googleauthor | So-Yeon Choi | - |
dc.contributor.googleauthor | Kyung-Tae Jung | - |
dc.contributor.googleauthor | Jong-Seon Park | - |
dc.contributor.googleauthor | Pum-Joon Kim | - |
dc.contributor.googleauthor | Jong-Min Lee | - |
dc.contributor.googleauthor | Myung-Ho Jeong | - |
dc.contributor.googleauthor | Eun-Seok Shin | - |
dc.contributor.googleauthor | Hyeon-Cheol Gwon | - |
dc.contributor.googleauthor | Kyoo-Rok Han | - |
dc.contributor.googleauthor | Jei-Keon Chae | - |
dc.contributor.googleauthor | Woo-Shik Kim | - |
dc.contributor.googleauthor | Dong-Ju Choi | - |
dc.contributor.googleauthor | Bum-Kee Hong | - |
dc.contributor.googleauthor | Si-Wan Choi | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.identifier.doi | 10.1016/j.clinthera.2020.07.013 | - |
dc.contributor.localId | A04394 | - |
dc.contributor.localId | A00876 | - |
dc.relation.journalcode | J00614 | - |
dc.identifier.eissn | 1879-114X | - |
dc.identifier.pmid | 32921501 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0149291820303477 | - |
dc.subject.keyword | hyperlipidemia | - |
dc.subject.keyword | impaired fasting glucose | - |
dc.subject.keyword | new-onset diabetes mellitus | - |
dc.subject.keyword | pitavastatin | - |
dc.contributor.alternativeName | Hong, Bum Kee | - |
dc.contributor.affiliatedAuthor | 홍범기 | - |
dc.contributor.affiliatedAuthor | 김재훈 | - |
dc.citation.volume | 42 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 2036 | - |
dc.citation.endPage | 2048 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, Vol.42(10) : 2036-2048, 2020-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.